HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 292/6/L1590    most recent 00365.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Kariya, C. Articles by Day, B. J. Search for Related Content PubMed PubMed Citation Articles by Kariya, C. Articles by Day, B. J.

A role for CFTR in the elevation of glutathione levels in the lung by oral glutathione administration

Departments of ¹Medicine and ²Immunology, National Jewish Medical and Research Center, Departments of ³Medicine, ⁴Immunology, and ⁵Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, Colorado; and ⁶Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio

Submitted 15 September 2006 ; accepted in final form 4 March 2007

The cystic fibrosis transmembrane conductance regulator (CFTR) protein is the only known apical glutathione (GSH) transporter in the lung. The purpose of these studies was to determine whether oral GSH or glutathione disulfide (GSSG) treatment could increase lung epithelial lining fluid (ELF) GSH levels and whether CFTR plays a role in this process. The pharmacokinetic profile of an oral bolus dose of GSH (300 mg/kg) was determined in mice. Plasma, ELF, bronchoalveolar lavage (BAL) cells, and lung tissue were analyzed for GSH content. There was a rapid elevation in the GSH levels that peaked at 30 min in the plasma and 60 min in the lung, ELF, and BAL cells after oral GSH dosing. Oral GSH treatment produced a selective increase in the reduced and active form of GSH in all lung compartments examined. Oral GSSG treatment (300 mg/kg) resulted in a smaller increase of GSH levels. To evaluate the role of CFTR in this process, Cftr knockout (KO) mice and gut-corrected Cftr KO-transgenic (Tg) mice were given an oral bolus dose of GSH (300 mg/kg) and compared with wild-type mice for changes in GSH levels in plasma, lung, ELF, and BAL cells. There was a twofold increase in plasma, a twofold increase in lung, a fivefold increase in ELF, and a threefold increase in BAL cell GSH levels at 60 min in wild-type mice; however, GSH levels only increased by 40% in the plasma, 60% in the lung, 50% in the ELF, and twofold in the BAL cells within the gut-corrected Cftr KO-Tg mice. No change in GSH levels was observed in the uncorrected Cftr KO mice. These studies suggest that CFTR plays an important role in GSH uptake from the diet and transport processes in the lung.

nutrition; transport; high-performance liquid chromatography; mice; cystic fibrosis; antioxidant; cystic fibrosis transmembrane conductance regulator

This article has been cited by other articles:

				E. M. Bradford, M. A. Sartor, L. R. Gawenis, L. L. Clarke, and G. E. Shull Reduced NHE3-mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice Am J Physiol Gastrointest Liver Physiol, April 1, 2009; 296(4): G886 - G898. [Abstract] [Full Text] [PDF]